{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:58:57Z","timestamp":1790787537801,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chronic active Epstein-Barr virus (CAEBV) disease is a high-mortality disease, which is characterized by persistent infectious mononucleosis-like symptoms. There is no standard treatment for CAEBV and allogeneic hematopoietic stem cell transplantation (HSCT) was considered the only potentially therapeutic approach. PD-1 inhibitors have achieved high response in many Epstein-Barr virus-related diseases. In this single-center retrospective analysis, we report the outcomes of PD-1 inhibitors treatment of CAEBV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All CAEBV patients without hemophagocytic lymphohistiocytosis (HLH), who were treated with PD-1 inhibitors in our center between 6\/1\/2017 and 12\/31\/2021, were retrospectively analyzed. The efficacy and safety of the PD-1 inhibitors were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the sixteen patients with a median age at onset of 33 years (range, 11-67 years), twelve patients responded to PD-1 inhibitors and the median progression-free survival (PFS) was 11.1 months (range, 4.9-54.8 months). Three achieved clinical complete response (clinical CR), as well as molecular CR. Five patients achieved and remained partial response (PR), and four converted from PR to no response (NR). For three CR patients, the median time and cycles from the first application of PD-1 inhibitor to clinical CR were 6 weeks (range, 4-10 weeks) and 3 cycles (range, 2-4 cycles), and molecular CR was achieved after a median of 16.7 weeks (range, 6.1-18.4 weeks) and 5 cycles (range, 3-6 cycles) of PD-1 inhibitor infusion. No immune-related adverse events have been observed except for one patient who suffered immune-related pancreatitis. There was no correlation of treatment outcome with blood count, liver function, LDH, cytokine or ferritin levels. NK cell function, PD-L1 expression in tumor tissue and gene mutation possibly correlated with treatment response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In patients with CAEBV, PD-1 inhibitors have tolerable toxicity and comparable outcomes while improving quality of life and financial toxicity. Larger prospective studies and longer follow-up time is needed to be conducted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1093719","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T04:23:13Z","timestamp":1678422193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yaxian","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.2.280","article-title":"Clinical and virologic characteristics of chronic active Epstein-Barr virus infection","volume":"98","author":"Kimura","year":"2001","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.3390\/cancers12113202","article-title":"Chronic active Epstein-Barr virus infection: Is it immunodeficiency, malignancy, or both","volume":"12","author":"Fujiwara","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01867","article-title":"Chronic active Epstein\u2013Barr virus disease","volume":"8","author":"Kimura","year":"2017","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00014","article-title":"Advances in the study of chronic active Epstein-Barr virus infection: Clinical features under the 2016 WHO classification and mechanisms of development","volume":"7","author":"Arai","year":"2019","journal-title":"Front Pediatr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2017.03.15","article-title":"Epstein-Barr Virus-associated lymphoproliferative disorders: Review and update on 2016 WHO classification","volume":"51","author":"Kim","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-associated T\/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: Prospective analysis of 108 cases","volume":"119","author":"Kimura","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-316745","article-title":"Characterization and treatment of chronic active Epstein-Barr virus disease: A 28-year experience in the united states","volume":"117","author":"Cohen","year":"2011","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-785931","article-title":"How I treat T-cell chronic active Epstein-Barr virus disease","volume":"131","author":"Bollard","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2192-6","article-title":"How we treat chronic active Epstein-Barr virus infection","volume":"105","author":"Sawada","year":"2017","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/biom12030397","article-title":"The Epstein-Barr virus hacks immune checkpoints: Evidence and consequences for lymphoproliferative disorders and cancers","volume":"12","author":"Biggi","year":"2022","journal-title":"Biomolecules"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive b-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00405","article-title":"Transcriptomic abnormalities in Epstein Barr virus associated T\/NK lymphoproliferative disorders","volume":"6","author":"de Mel","year":"2018","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: An open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003886","article-title":"Nivolumab treatment of relapsed\/refractory Epstein-Barr virus\u2013associated hemophagocytic lymphohistiocytosis in adults","volume":"135","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001451","article-title":"Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification","volume":"4","author":"Yonese","year":"2020","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41392-020-00331-3","article-title":"Combination of anti-PD-1 antibody with p-GEMOX as a potentially effective immunochemotherapy for advanced natural killer\/T cell lymphoma","volume":"5","author":"Cai","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/10428194.2016.1179297","article-title":"Clinicopathological categorization of Epstein-Barr virus-positive T\/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications","volume":"58","author":"Paik","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1093719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T04:23:15Z","timestamp":1678422195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1093719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2023.1093719"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1093719","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"article-number":"1093719"}}